Prescription trends in Japanese advanced Parkinson's disease patients with non-motor symptoms: J-FIRST. [PDF]
PLoS ONEBackgroundNon-motor symptoms (NMS) are important factors when selecting treatments for patients with advanced Parkinson's disease (PD). We sought to elucidate the prescribing practices for advanced PD patients with NMS in Japanese clinical practice ...
Masahiro Nomoto +10 more
doaj +2 more sources
Analysis of L-DOPA and droxidopa binding to human β2-adrenergic receptor
Biophysical Journal, 2021 Over the last two decades, an increasing number of studies has been devoted to a deeper understanding of the molecular process involved in the binding of various agonists and antagonists to active and inactive conformations of β2-adrenergic receptor (β2AR).
Akash Deep Biswas +3 more
semanticscholar +5 more sources
Contamination of the Norepinephrine Prodrug Droxidopa by Dihydroxyphenylacetaldehyde [PDF]
Clinical Chemistry, 2010 AbstractBackground: l-Threo-3,4-dihydroxyphenylserine (L-DOPS, droxidopa) is a norepinephrine (NE) prodrug under development to treat orthostatic hypotension. 3,4-Dihydroxyphenylacetaldehyde (DOPAL), an endogenous catecholaldehyde produced by enzymatic oxidative deamination of dopamine, is toxic to catecholaminergic neurons. Based on the observation of
Courtney Holmes +3 more
+6 more sources
Droxidopa for refractory neurogenic orthostatic hypotension in amyloid light chain amyloidosis
American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2023 Neurogenic orthostatic hypotension (nOH) secondary to amyloidosis is a rare condition associated with significant blood pressure (BP) drops and problematic symptoms for patients.
Hien Ha, Nguyen L Nguyen
openalex +3 more sources
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? [PDF]
Clinical Autonomic Research, 2017 Horacio Kaufmann
openalex +4 more sources
Droxidopa in neurogenic orthostatic hypotension [PDF]
Expert Review of Cardiovascular Therapy, 2015 Neurogenic orthostatic hypotension (nOH) is a fall in blood pressure (BP) on standing due to reduced norepinephrine release from sympathetic nerve terminals. nOH is a feature of several neurological disorders that affect the autonomic nervous system, most notably Parkinson disease (PD), multiple system atrophy (MSA), pure autonomic failure (PAF), and ...
Horacio Kaufmann +2 more
openalex +4 more sources
Analytical SciencesThe electrochemical behavior of catecholamines involves an electron transfer-chemical reaction-electron transfer (ECE) mechanism, characterized by two reversible redox reactions interspersed with an irreversible chemical reaction. Previously, we reported
YinQiang Yin Shu +2 more
openalex +2 more sources
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease [PDF]
Movement Disorders Clinical Practice, 2018 Robert A Hauser, Steven Vernino
exaly +2 more sources
Compliance with National and International Guidelines in the Treatment of Nonmotor Symptoms in Late-Stage Parkinson's Disease. [PDF]
Parkinsons Dis, 2023 Background. National as well as international Parkinson’s disease (PD) treatment guidelines are available to guide clinicians. Previous research has shown that nonmotor symptoms (NMS) are pronounced in late‐stage PD and has suggested that current treatment is insufficient and could be improved. Objectives.
Rosqvist K, Odin P.
europepmc +2 more sources
Neurogenic orthostatic hypotension – management update and role of droxidopa
Therapeutics and Clinical Risk Management, 2015 Orthostatic hypotension (OH) is defined as a significant decrease in blood pressure (BP) during the first 3 minutes of standing or a head up on a tilt table. Symptoms of OH are highly variable, ranging from mild light-headedness to recurrent syncope.
Vijay K. Sharma, Joy Vijayan
openalex +5 more sources